ClinicalTrials.gov
ClinicalTrials.gov Menu

Effects of Caffeine on Methacholine Challenge and Exhaled Nitric Oxide Levels.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01057875
Recruitment Status : Completed
First Posted : January 27, 2010
Last Update Posted : October 7, 2010
Sponsor:
Information provided by:
University of Saskatchewan

Brief Summary:
To investigate whether or not the ingestion of caffeine with alter airway responsiveness to methacholine and/or change the level of exhaled nitric oxide.

Condition or disease Intervention/treatment Phase
Asthma Other: caffeine Other: No caffeine Not Applicable

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 15 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: The Effects of Caffeine on Exhaled Nitric Oxide Levels and Methacholine PC20
Study Start Date : January 2010
Actual Primary Completion Date : February 2010
Actual Study Completion Date : February 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Caffeine
U.S. FDA Resources

Arm Intervention/treatment
Experimental: coffee with caffeine Other: caffeine
Starbuck's Grande Pike Roast coffee
Placebo Comparator: decaffeinated coffee
Starbuck's Grande Pike Roast Decaf
Other: No caffeine
Starbuck's Grande Pike Roast Decaffeinated Coffee



Primary Outcome Measures :
  1. methacholine pc20 [ Time Frame: 1 hour post ingestion ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • clinical diagnosis of asthma
  • FEV1 greater than 65%

Exclusion Criteria:

  • asthma is poorly controlled
  • presence of other airway disease (e.g. COPD)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01057875


Locations
Canada, Saskatchewan
University of Saskatchewan
Saskatoon, Saskatchewan, Canada, S7N 0W8
Sponsors and Collaborators
University of Saskatchewan
Investigators
Principal Investigator: Donald W Cockcroft, MD University of Saskatchewan

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Donald Cockcroft, MD, University of Saskatchewan
ClinicalTrials.gov Identifier: NCT01057875     History of Changes
Other Study ID Numbers: BIO REB 09-186
First Posted: January 27, 2010    Key Record Dates
Last Update Posted: October 7, 2010
Last Verified: October 2010

Additional relevant MeSH terms:
Caffeine
Nitric Oxide
Methacholine Chloride
Central Nervous System Stimulants
Physiological Effects of Drugs
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Purinergic P1 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Anti-Asthmatic Agents
Respiratory System Agents
Free Radical Scavengers
Antioxidants
Endothelium-Dependent Relaxing Factors
Vasodilator Agents
Gasotransmitters
Protective Agents
Miotics
Parasympathomimetics
Bronchoconstrictor Agents
Muscarinic Agonists
Cholinergic Agonists
Cholinergic Agents